UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (505) 505
science & technology (419) 419
life sciences & biomedicine (411) 411
male (378) 378
female (327) 327
ramipril - therapeutic use (316) 316
middle aged (279) 279
ramipril (277) 277
angiotensin-converting enzyme inhibitors - therapeutic use (268) 268
aged (235) 235
ramipril - adverse effects (221) 221
hypertension - drug therapy (205) 205
angiotensin-converting enzyme inhibitors - adverse effects (199) 199
cardiovascular system & cardiology (163) 163
blood pressure - drug effects (149) 149
adult (146) 146
ramipril - administration & dosage (136) 136
treatment outcome (133) 133
antihypertensive agents - therapeutic use (129) 129
hypertension (126) 126
drug therapy, combination (117) 117
double-blind method (111) 111
cardiac & cardiovascular systems (101) 101
pharmacology & pharmacy (100) 100
risk factors (91) 91
antihypertensive agents - adverse effects (90) 90
abridged index medicus (87) 87
angiotensin-converting enzyme inhibitors - administration & dosage (85) 85
ramipril - pharmacology (82) 82
drug therapy (80) 80
animals (77) 77
ace inhibitors (74) 74
blood pressure (73) 73
peripheral vascular disease (73) 73
hypertension - physiopathology (72) 72
angiotensin-converting enzyme inhibitors - pharmacology (71) 71
benzimidazoles - therapeutic use (67) 67
prospective studies (66) 66
general & internal medicine (63) 63
antihypertensive agents - administration & dosage (59) 59
medicine, general & internal (59) 59
benzoates - therapeutic use (57) 57
research (54) 54
follow-up studies (53) 53
angiotensin ii type 1 receptor blockers - therapeutic use (51) 51
aged, 80 and over (50) 50
diabetes (50) 50
enzymes (50) 50
angiotensin (49) 49
time factors (49) 49
angiotensin-converting enzyme inhibitors (46) 46
dose-response relationship, drug (46) 46
hypertension - complications (45) 45
rats (45) 45
cardiovascular diseases - prevention & control (44) 44
randomized controlled trials as topic (43) 43
telmisartan (43) 43
urology & nephrology (43) 43
cardiovascular diseases - drug therapy (42) 42
dosage and administration (42) 42
heart failure - drug therapy (42) 42
heart failure (40) 40
medicine & public health (40) 40
cardiovascular disease (39) 39
cardiovascular diseases (39) 39
renin-angiotensin system - drug effects (38) 38
internal medicine (37) 37
care and treatment (34) 34
health aspects (34) 34
benzimidazoles - adverse effects (33) 33
clinical trials (33) 33
bridged bicyclo compounds - adverse effects (32) 32
bridged bicyclo compounds - therapeutic use (32) 32
prevention (32) 32
antihypertensive agents - pharmacology (31) 31
benzoates - adverse effects (31) 31
angiotensin ii type 1 receptor blockers - adverse effects (30) 30
mortality (29) 29
cardiology (28) 28
complications and side effects (28) 28
heart attacks (28) 28
clinical trials as topic (27) 27
myocardial infarction - drug therapy (27) 27
adolescent (26) 26
drug combinations (26) 26
enzyme inhibitors (26) 26
heart rate - drug effects (26) 26
myocardial infarction (26) 26
renin-angiotensin system (26) 26
angioedema - chemically induced (25) 25
cardiovascular (25) 25
diabetes mellitus, type 2 - drug therapy (24) 24
medical research (24) 24
kidney diseases (23) 23
retrospective studies (23) 23
tetrazoles - therapeutic use (23) 23
benzimidazoles - administration & dosage (22) 22
medicine (22) 22
studies (22) 22
hydrochlorothiazide - administration & dosage (21) 21
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (606) 606
German (23) 23
Russian (10) 10
French (6) 6
Spanish (6) 6
Hungarian (2) 2
Swedish (2) 2
Czech (1) 1
Danish (1) 1
Italian (1) 1
Japanese (1) 1
Lithuanian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
.... Outcomes were the same with telmisartan and ramipril, and there were more adverse events with combination therapy... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9638, pp. 547 - 553
.... We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Ramipril - administration & dosage | Proteinuria - chemically induced | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Benzimidazoles - therapeutic use | Kidney - drug effects | Double-Blind Method | Diabetes Mellitus - drug therapy | Proteinuria - metabolism | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Benzoates - administration & dosage | Creatinine - blood | Aged | Urine | Drugs | Studies | Kidneys | Disease | Clinical trials | Risk | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2008, Volume 359, Issue 12, pp. 1225 - 1237
In a multicenter trial, 20,332 patients who had recently had an ischemic stroke were randomly assigned to receive either telmisartan or placebo. All patients... 
MORTALITY | HIGH-RISK PATIENTS | DESIGN | RAMIPRIL | RATIONALE | DOUBLE-BLIND | VASCULAR EVENTS | COMBINATION | UMCG Approved | BLOOD-PRESSURE | RANDOMIZED TRIAL | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Secondary Prevention | Heart Failure - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Treatment Failure | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Heart Failure - epidemiology | Benzimidazoles - therapeutic use | Stroke - prevention & control | Kaplan-Meier Estimate | Stroke - drug therapy | Diabetes Mellitus - epidemiology | Creatinine - blood | Potassium - blood | Aged | Myocardial Infarction - prevention & control | Stroke (Disease) | Prevention | Usage | Health aspects | Telmisartan | Medical research | Stroke | Blood pressure | Index Medicus | Abridged Index Medicus | Blood Pressure | Creatinine | Recurrence | Benzimidazoles | Cardiovascular Diseases | Benzoates | Diabetes Mellitus | Geriatry and gerontology | Life Sciences | Human health and pathology | Myocardial Infarction | Angiotensin-Converting Enzyme Inhibitors | Heart Failure | Potassium | Cardiology and cardiovascular system | Original | Benzimidazoles/adverse effects/therapeutic use | Diabetes Mellitus/epidemiology | Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use | Recurrence/prevention & control | Stroke/drug therapy/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Creatinine/blood | Potassium/blood | Blood Pressure/drug effects | Cardiovascular Diseases/epidemiology/mortality/prevention & control | Benzoates/adverse effects/therapeutic use | Myocardial Infarction/epidemiology/prevention & control | Kaplan-Meiers Estimate | MEDICAL AND HEALTH SCIENCES | Heart Failure/epidemiology/prevention & control
Journal Article
The Lancet (British edition), ISSN 0140-6736, 06/2017, Volume 389, Issue 10085, pp. 2226 - 2237
Summary Background Studies have challenged the appropriateness of accepted blood pressure targets. We hypothesised that different levels of low blood pressure... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Randomized Controlled Trials as Topic - methods | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Hospitalization - statistics & numerical data | Hypertension - drug therapy | Male | Multicenter Studies as Topic | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Hypotension - mortality | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Cardiovascular Diseases - physiopathology | Antihypertensive Agents - therapeutic use | Hypotension - chemically induced | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Telmisartan | Hypotension - complications | Aged | Blood pressure | Hospitals | Research institutes | Germany | Myocardial infarction | Heart | Intervention | Syngeneic grafts | Funding | Clinical trials | Cardiovascular disease | Blood | Optimization | Risk factors | Clinical outcomes | Incidence | Recruitment | Peptidyl-dipeptidase A | Risk assessment | Failure analysis | Pretreatment | Heart diseases | Hypertension | Cerebral infarction | Stroke | Risk groups | Adjustment | Categories | Mortality | Regression analysis | Patients | Variance analysis | Oral cavity | Inhibitors | Converting | Angiotensin | Death | Fatalities | Infarction | Cardiovascular diseases | Health risk assessment | Heart attacks | Risk | Heart failure | Health risks | Coronary vessels | Diabetes | Mercury | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
American Journal of Cardiovascular Drugs, ISSN 1175-3277, 04/2010, Volume 10, Issue 2, pp. 95 - 103
Background The Polycap™ (polypill; aspirin [acetylsalicylic acid], ramipril, simvastatin, atenolol, and hydrochlorothiazide) was found to be safe and effective... 
Drug-interactions | Ramipril, pharmacokinetics | Aspirin, pharmacokinetics | Hydrochlorothiazide, pharmacokinetics | Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin, pharmacokinetics | Salicylic-acid, pharmacokinetics | Atenolol, pharmacokinetics | Risk-factors | Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin, drug interactions | Simvastatin, pharmacokinetics | Cardiovascular-disorders, treatment | Pharmacotherapy | Medicine & Public Health | Cardiology | Pharmacology/Toxicology | Cardiac & Cardiovascular Systems | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hydrochlorothiazide - pharmacokinetics | Simvastatin - adverse effects | Area Under Curve | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Aspirin - pharmacokinetics | Biological Availability | Male | Aspirin - administration & dosage | Ramipril - administration & dosage | Young Adult | Capsules | Drug Interactions | Aspirin - adverse effects | Atenolol - pharmacokinetics | Platelet Aggregation Inhibitors - administration & dosage | Adult | Platelet Aggregation Inhibitors - pharmacokinetics | Atenolol - administration & dosage | Ramipril - adverse effects | Tandem Mass Spectrometry - methods | Platelet Aggregation Inhibitors - adverse effects | Hydrochlorothiazide - adverse effects | Cardiovascular Diseases - etiology | Hypolipidemic Agents - adverse effects | Administration, Oral | Simvastatin - administration & dosage | Risk Factors | Ramipril - pharmacokinetics | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Simvastatin - pharmacokinetics | Antihypertensive Agents - adverse effects | Cross-Over Studies | Adolescent | Hypolipidemic Agents - administration & dosage | Atenolol - adverse effects | Chromatography, Liquid - methods | Hypolipidemic Agents - pharmacokinetics | Drug Combinations | Prevention | Complications and side effects | Drug interactions | Dosage and administration | Research | Cardiovascular diseases | Risk factors | Cardiovascular agents | Index Medicus
Journal Article
Journal Article
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 02/2007, Volume 49, Issue 2, pp. 276 - 284
Thiazide diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers all cause reactive rises in plasma renin activity. We... 
Hypertension | Aliskiren | Renin inhibitor | Renin-angiotensin-aldosterone system | Combination therapy | Plasma renin activity | Ambulatory blood pressure measurement | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Amides | Hypertension - drug therapy | Male | Sodium Chloride Symporter Inhibitors - adverse effects | Sodium Chloride Symporter Inhibitors - therapeutic use | Biphenyl Compounds - therapeutic use | Hypertension - blood | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Drug Therapy, Combination | Hypertension - diagnosis | Ramipril - adverse effects | Hydrochlorothiazide - adverse effects | Fumarates - therapeutic use | Fumarates - adverse effects | Antihypertensive Agents - therapeutic use | Renin - blood | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Fumarates - blood | Renin - antagonists & inhibitors | Tetrazoles - therapeutic use | Aged | Patient Compliance | Tetrazoles - adverse effects | Blood Pressure Monitoring, Ambulatory | Hydrochlorothiazide - therapeutic use | Index Medicus
Journal Article
9.